Evidence mapPaperPMID 41211588Full record

ReviewInternational journal of nanomedicine2025

Stimuli-Responsive MXene Nanomaterials for Advanced Antitumor Drug Delivery Systems.

Peng Deng, Zhihong Ling, Fei Fang, Jishi Ruan, Chuanjun Yang, Rong Hu, Jing Zhou, Peizheng Xiong

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Peng Deng *Department of Oncology, The Fourth People's Hospital of Sichuan Province, Chengdu, People's Republic of China.
Zhihong Ling *Department of Oncology, The Fourth People's Hospital of Sichuan Province, Chengdu, People's Republic of China.
Fei FangDepartment of General Surgery, The 955th Hospital of Army, Changdu, People's Republic of China.
Jishi RuanDepartment of Oncology, The Fourth People's Hospital of Sichuan Province, Chengdu, People's Republic of China.
Chuanjun YangDepartment of Oncology, The Fourth People's Hospital of Sichuan Province, Chengdu, People's Republic of China.
Rong HuDepartment of Oncology, The Fourth People's Hospital of Sichuan Province, Chengdu, People's Republic of China.
Jing ZhouDepartment of Endocrinology, The Fourth People's Hospital of Sichuan Province, Chengdu, People's Republic of China.
Peizheng XiongDepartment of Otorhinolaryngology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MXene, a novel class of two-dimensional nanomaterials, has garnered significant attention for antitumor drug delivery due to its exceptional properties, including high specific surface area, excellent photothermal conversion efficiency, and tunable surface chemistry. Given the limitations of traditional cancer therapies, such as systemic toxicity and poor tumor targeting, MXene-based nanocarriers offer a promising solution. This review summarizes the intelligent responsive nano-drug delivery system constructed with MXene nanomaterials as a drug carrier material, as well as the research progress of endogenous stimulation (pH value and redox microenvironment), exogenous stimulation (photoheat and ultrasound), and multistimulus-responsive MXene nanomaterials. The aim is to provide valuable insights and inspirations for the further development of effective and safe MXene nanomaterials with antitumor properties.

Indexed as

Antineoplastic AgentsDrug CarriersDrug Delivery SystemsNanostructuresNeoplasmsAnimalsHumansHydrogen-Ion ConcentrationNitritesTransition ElementsAntineoplastic AgentsDrug CarriersMXeneNitritesTransition Elementsantitumordrug delivery systemMXenereviewstimuli-response

Identifiers

PMID41211588
PMCPMC12595973

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.